Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that preclinical results for its Placental eXpanded (PLX) RAD cells in the treatment of bone marrow disease have been published in peer reviewed journal PLOS ONE.

A study titled "Mitigation of lethal radiation syndrome in mice by intramuscular injection of 3D cultured adherent human placental stromal cells" was published on June 18th in the open access journal PLOS ONE (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066549). This animal study on acute radiation syndrome (ARS) was performed by Professor Raphael Gorodetsky and his team at the Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology at Hadassah Medical Center, Jerusalem in collaboration and the support of Pluristem Therapeutics. The findings of the published study suggest that intramuscular treatment with Pluristem's PLX-RAD cells may serve as a highly effective "off the shelf" therapy to mitigate ARS.

The treatment of intramuscular injection of PLX-RAD cells increased the survival of 7.7Gy irradiated mice from about 27% to about 98% (P